Calidi Biotherapeutics Raises $25M in Series B Funding
Summary
The remaining commitment is conditioned upon the consummation of the previously announced business combination between First Light Acquisition Group (NYSEAMERICAN: FLAG) and Calidi. The company intends to use the funds to continue the advancement of its pipeline including CLD-101, CLD-201, and CLD-202, which utilize a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications. Led by CEO Allan Camaisa, Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that works on the effective delivery and potentiation of oncolytic viruses for targeted therapy against difficult-to-treat cancers. The company specializes in clinical development of allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications. Calidi’s off-the-shelf, cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses currently in development leading to enhanced efficacy and improved patient safety.